Latest news with #CRDMO
Business Standard
21-07-2025
- Business
- Business Standard
Anthem Biosciences jumps on debut
Shares of Anthem Biosciences were currently trading at Rs 726.35 at 10:21 IST on the BSE, representing a premium of 27.43% compared with the issue price of Rs 570. The scrip was listed at Rs 723.10, exhibiting a premium of 26.86% to the issue price. So far, the stock has hit a high of Rs 746.70 and a low of Rs 723.05. On the BSE, over 25.90 lakh shares of the company were traded in the counter so far. The initial public offer of Anthem Biosciences was subscribed 63.86 times. The issue opened for bidding on 14 July 2025 and it closed on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share. The IPO is a full offer for sale of 5,95,61,404 equity shares at the upper price, amounting to Rs 3,395 crore. The company will not receive any funds from the offer; all proceeds will go to the selling shareholders based on the shares they offered. The promoters and promoter group hold a total of 43,17,47,949 equity shares, making up 76.87% of the pre-offer issued and paid-up equity share capital. Their shareholding after the IPO is expected to be around 74.69%. Anthem Biosciences is a tech-oriented CRDMO, providing drug discovery and manufacturing services, as well as specialty ingredients like probiotics, enzymes, and peptides. In FY25, CRDMO contributed 81.65% of its revenue. It serves over 550 clients in more than 44 countries, with Europe and North America being key markets. Supported by green chemistry and a partnership with Davos Pharma in the U.S., the company is growing its capacity and working on technologies like RNAi and ADCs. Ahead of the IPO, Anthem Biosciences on Friday, 11 July 2025, raised Rs 1,016.02 crore from anchor investors. The board allotted 1.78 crore shares at Rs 570 each to 60 anchor investors. The firm reported a consolidated net profit of Rs 451.26 crore and sales of Rs 1,844.55 crore for the twelve months ended on 31 March 2025.
&w=3840&q=100)
Business Standard
21-07-2025
- Business
- Business Standard
Anthem Biosciences shares list at 27% premium, miss IPO GMP forecasts
Anthem Biosciences IPO listing, Anthem Biosciences share price: Shares of innovation-driven and technology-focused company Anthem Biosciences made a solid D-Street debut on Monday, July 21, following the completion of its initial public offering (IPO). The company's shares listed at ₹723.10 per share on the BSE, reflecting a premium of ₹153.10 or 26.86 per cent over the issue price of ₹570 per share. On the National Stock Exchange (NSE), Anthem Biosciences shares listed at a mildly lower premium of ₹153.05 or 26.85 per cent at ₹723.05 per share over the issue price. Anthem Biosciences IPO listing came below the grey market estimate. Ahead of their debut on the bourses, the unlisted shares of Anthem Biosciences were exchanging hands at around ₹749 per share, reflecting a grey market premium (GMP) of ₹179 per share or nearly 31.40 per cent over the issue price of ₹570 per share, showed the sources that track unofficial market activities. Anthem Biosciences IPO details Anthem Biosciences IPO comprised entirely an offer-for-sale (OFS) with promoters and shareholders divesting up to 59.6 million equity shares estimated to be worth ₹3,395 crore. The public issue was offered at a price band of ₹540–570 with a lot size of 26 shares, and was open for subscription from July 14, 2025, till July 16, 2025. Anthem Biosciences received strong demand from investors for its public issue as it got oversubscribed by 63.86 times. The demand was led by the qualified institutional buyers (QIBs), who bid for 182.65 times the category reserved for them, showed the NSE data. Anthem Biosciences, as outlined in its red herring prospectus (RHP), will not use any proceeds from the public issue, and it will be given to the promoters and shareholders selling their stakes through the OFS. About Anthem Biosciences Incorporated in 2006, Anthem Biosciences is a contract research, development, and manufacturing organisation (CRDMO) serving global customers. The company manufactures specialised fermentation-based APIs, including probiotics and enzymes. Anthem Biosciences has a diverse customer base, including biotech firms and large pharmaceutical companies, spanning over 44 countries. As of September 2024, the company had 196 projects and over 425 customers in its CRDMO business. The company holds one patent in India and seven overseas, with 24 pending global patent applications.
News18
21-07-2025
- Business
- News18
Anthem Biosciences IPO Lists At 26.8% Premium: Should You Buy, Hold, Or Sell?
Anthem Biosciences Share Price: Its shares were listed at Rs 723 apiece on the BSE, a premium of 26.85 per cent as against the IPO issue price of Rs 570. Anthem Biosciences Share Price: Anthem Biosciences Ltd made a strong stock market debut on Monday, July 21. Its shares were listed at Rs 723 apiece on the BSE, a premium of 26.85 per cent as against the IPO issue price of Rs 570. The share prices rose further and were trading at Rs 730 apiece, as of 10:14 am. The stock was also listed at Rs 723.05 apiece on the NSE. Its market capitalisation (m-cap) stood at Rs 40,997.53 crore. Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organisation (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It also manufactures and sells complex specialised fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. Anthem Biosciences IPO Listing: Should You Buy, Hold Or Sell? Brokerages remain largely optimistic about Anthem Biosciences, citing its strong financial track record, niche positioning in the CRDMO space, and robust pipeline. However, a few have flagged concerns over valuations and margin pressures. However, it cautioned that growth is dependent on the success of pipeline molecules and regulatory compliance, among other risks. Anand Rathi Shares & Stock Broking noted that Anthem is 'positioned to cater in CROs and CRDMO segment — the crucial players in the pharma and biotechnology industries — wherein it is being niche player with high entry barriers through its differentiated FFS model, long-term relationship, strong R&D, innovation and technology-driven approach." The brokerage firm added that the company has outperformed peers in profitability and is likely to maintain that edge. Anthem Biosciences IPO: More Info The IPO was open for public subscription between July 14 and July 16. It received a strong 67.42 times subscription, garnering bids for 2,81,49,30,794 shares as against the 4,17,50,321 shares on offer. The retail and NII participation stood at 5.98x and 44.70x, respectively. The QIB category received a 192.80x subscription. The price band of the mainboard IPO, which aimed to raise Rs 3,395 crore, was fixed in the range of Rs 540 to Rs 570. The IPO is entirely an offer-for-sale (OFS). So, the company will not receive any funds from the issue and the proceeds will go to the selling shareholders. view comments Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Business Standard
17-07-2025
- Business
- Business Standard
Anthem Biosciences IPO ends with 63.86x subscription
The offer received bids for 281.45 crore shares as against 4.40 crore shares on offer. The initial public offer of Anthem Biosciences received bids for 2,81,45,24,128 shares as against 4,40,70,682 shares on offer. The issue was subscribed 63.86 times. The Qualified Institutional Buyers (QIBs) category was subscribed 182.65 times. The Non-Institutional Investors (NIIs) category was subscribed 42.36 times. The Retail Individual Investors (RIIs) category was subscribed 5.64 times. The issue opened for bidding on 14 July 2025 and it closed on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share. The IPO is a full offer for sale of 5,95,61,404 equity shares at the upper price, amounting to Rs 3,395 crore. The company will not receive any funds from the offer; all proceeds will go to the selling shareholders based on the shares they offered. The promoters and promoter group hold a total of 43,17,47,949 equity shares, making up 76.87% of the pre-offer issued and paid-up equity share capital. Their shareholding after the IPO is expected to be around 74.69%. Anthem Biosciences is a tech-oriented CRDMO, providing drug discovery and manufacturing services, as well as specialty ingredients like probiotics, enzymes, and peptides. In FY25, CRDMO contributed 81.65% of its revenue. It serves over 550 clients in more than 44 countries, with Europe and North America being key markets. Supported by green chemistry and a partnership with Davos Pharma in the U.S., the company is growing its capacity and working on technologies like RNAi and ADCs. Ahead of the IPO, Anthem Biosciences on Friday, 11 July 2025, raised Rs 1,016.02 crore from anchor investors. The board allotted 1.78 crore shares at Rs 570 each to 60 anchor investors. The firm reported a consolidated net profit of Rs 451.26 crore and sales of Rs 1,844.55 crore for the twelve months ended on 31 March 2025.
Business Standard
16-07-2025
- Business
- Business Standard
Anthem Biosciences IPO subscribed 63.86 times
The offer received bids for 281.44 crore shares as against 4.40 crore shares on offer. The initial public offer of Anthem Biosciences received bids for 2,81,44,34,740 shares as against 4,40,70,682 shares on offer, according to stock exchange data at 17:30 IST on Wednesday (16 July 2025). The issue was subscribed 63.86 times. The issue opened for bidding on 14 July 2025 and it will close on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share. An investor can bid for a minimum of 26 equity shares and in multiples thereof. The IPO is a full offer for sale of 5,95,61,404 equity shares at the upper price, amounting to Rs 3,395 crore. The company will not receive any funds from the offer; all proceeds will go to the selling shareholders based on the shares they offered. The promoters and promoter group hold a total of 43,17,47,949 equity shares, making up 76.87% of the pre-offer issued and paid-up equity share capital. Their shareholding after the IPO is expected to be around 74.69%. Anthem Biosciences is a tech-oriented CRDMO, providing drug discovery and manufacturing services, as well as specialty ingredients like probiotics, enzymes, and peptides. In FY25, CRDMO contributed 81.65% of its revenue. It serves over 550 clients in more than 44 countries, with Europe and North America being key markets. Supported by green chemistry and a partnership with Davos Pharma in the U.S., the company is growing its capacity and working on technologies like RNAi and ADCs. Ahead of the IPO, Anthem Biosciences on Friday, 11 July 2025, raised Rs 1,016.02 crore from anchor investors. The board allotted 1.78 crore shares at Rs 570 each to 60 anchor investors. The firm reported a consolidated net profit of Rs 451.26 crore and sales of Rs 1,844.55 crore for the twelve months ended on 31 March 2025.
